Wednesday, 17 Oct 2018

You are here

Rituximab May Halt ILD in Antisynthetase Syndrome Myositis

A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most. 

A retrospective analysis from the University of Pittsburgh and the Brigham and Women’s Hospital pooled their collective experience and analyzed data from 25 patients with AS-ILD, specifically assessing clinical, PFT, and chest CT outcomes using standardized scoring. 

All patients had antisynthetase antibodies (16 withJo-1, 6 PL-12, 3 PL-7). In 21/25 (84%), RTX was prescribed for recurrent or progressive ILD. CT findings included CT nonspecific interstitial pneumonia (NSIP; n = 13) and usual interstitial pneumonia (UIP)/fibrotic NSIP (n = 5), and 5 also had cryptogenic organizing pneumonia.

The 12 month outcomes, comparing pre- and post-RTX pulmonary variables, showed improvement in CT score (88%), FVC (79%), total lung capacity (from 56 ± 13 to 64 ± 13) the the glucocorticoid doses decreased from 18 ± 9 to 12 ± 12 mg/day.

DLCO (%) declined slightly at 1 year, but later increased from 42 ± 17 to 70 ± 20 at 3 years.

These uncontrolled and retrospective data provide preliminary evidence of RTX benefit when treating AS-ILD, a condition that is progressive in most patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

IL-6 for Adult Still's: A New Option?

Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.